Department of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, Purdue University, West Lafayette, IN 47907.
Purdue Institute for Integrative Neuroscience, Purdue University, Beijing, China, 100191.
J Neurosci. 2021 Dec 8;41(49):10194-10208. doi: 10.1523/JNEUROSCI.0564-21.2021. Epub 2021 Oct 29.
With the wide adoption of genomic sequencing in children having seizures, an increasing number of genetic variants have been revealed as genetic causes of epilepsy. Voltage-gated sodium channel Nav1.2, encoded by gene , is predominantly expressed in the pyramidal excitatory neurons and supports action potential (AP) firing. One recurrent genetic variant is L1342P, which was identified in multiple patients with epileptic encephalopathy and intractable seizures. However, the mechanism underlying L1342P-mediated seizures and the pharmacogenetics of this variant in human neurons remain unknown. To understand the core phenotypes of the L1342P variant in human neurons, we took advantage of a reference human-induced pluripotent stem cell (hiPSC) line from a male donor, in which L1342P was introduced by CRISPR/Cas9-mediated genome editing. Using patch-clamping and microelectrode array (MEA) recordings, we revealed that cortical neurons derived from hiPSCs carrying heterozygous L1342P variant have significantly increased intrinsic excitability, higher sodium current density, and enhanced bursting and synchronous network firing, suggesting hyperexcitability phenotypes. Interestingly, L1342P neuronal culture displayed a degree of resistance to the anticonvulsant medication phenytoin, which recapitulated aspects of clinical observation of patients carrying the L1342P variant. In contrast, phrixotoxin-3 (PTx3), a Nav1.2 isoform-specific blocker, can potently alleviate spontaneous and chemically-induced hyperexcitability of neurons carrying the L1342P variant. Our results reveal a possible pathogenic underpinning of Nav1.2-L1342P mediated epileptic seizures and demonstrate the utility of genome-edited hiPSCs as an platform to advance personalized phenotyping and drug discovery. A mounting number of genetic variants have been identified from patients with epilepsy, but how variants affect the function of human neurons contributing to seizures is still elusive. This study investigated the functional consequences of a recurring variant (L1342P) using human iPSC-derived neurons and revealed both intrinsic and network hyperexcitability of neurons carrying a mutant Nav1.2 channel. Importantly, this study recapitulated elements of clinical observations of drug-resistant features of the L1342P variant, and provided a platform for drug testing. Our study sheds light on cellular mechanism of seizures resulting from a recurring Nav1.2 variant, and helps to advance personalized drug discovery to treat patients carrying pathogenic variant.
随着基因组测序在癫痫患儿中的广泛应用,越来越多的遗传变异被揭示为癫痫的遗传原因。电压门控钠离子通道 Nav1.2 由基因编码,主要在锥体兴奋性神经元中表达,并支持动作电位 (AP) 发射。一种反复出现的遗传变异是 L1342P,它在患有癫痫性脑病和难治性癫痫的多个患者中被发现。然而,L1342P 介导的癫痫发作的机制以及该变体在人类神经元中的药物遗传学仍不清楚。为了了解 L1342P 变体在人类神经元中的核心表型,我们利用了来自男性供体的参考人类诱导多能干细胞 (hiPSC) 系,通过 CRISPR/Cas9 介导的基因组编辑引入了 L1342P。通过膜片钳和微电极阵列 (MEA) 记录,我们揭示了携带杂合 L1342P 变体的 hiPSC 衍生的皮质神经元具有显著增加的内在兴奋性、更高的钠电流密度以及增强的爆发和同步网络放电,提示存在过度兴奋表型。有趣的是,L1342P 神经元培养物对抗癫痫药物苯妥英表现出一定程度的耐药性,这反映了携带 L1342P 变体的患者的临床观察的某些方面。相比之下,phrixotoxin-3 (PTx3),一种 Nav1.2 同工型特异性阻滞剂,可以有效缓解携带 L1342P 变体的神经元的自发性和化学诱导性过度兴奋。我们的研究结果揭示了 Nav1.2-L1342P 介导的癫痫发作的可能致病基础,并证明了基因编辑 hiPSC 作为推进个性化表型和药物发现的平台的实用性。越来越多的遗传变异已从癫痫患者中鉴定出来,但变异如何影响导致癫痫发作的人类神经元的功能仍然难以捉摸。本研究使用人类 iPSC 衍生的神经元研究了一种反复出现的变异体 (L1342P) 的功能后果,并揭示了携带突变 Nav1.2 通道的神经元的内在和网络过度兴奋。重要的是,本研究再现了 L1342P 变体的耐药特征的临床观察的某些方面,并为药物测试提供了一个平台。我们的研究揭示了由反复出现的 Nav1.2 变异引起的癫痫发作的细胞机制,并有助于推进针对携带致病变异体的患者的个性化药物发现。